Guerbet: 1st quarter 2019 revenue
April 18 2019 - 12:10PM
Guerbet: 1st quarter 2019 revenue
1st quarter 2019 revenue
Year off to a good start:
- €197.3 million; +7.7% at current exchange rates
- €195.4 million; +6.7% at constant exchange rates
Villepinte, 18 April 2019 -
Guerbet (FR0000032526 GBT), a global specialist in
contrast agents and solutions for medical imaging, is reporting
revenue for the 1st quarter 2019. At March 31, reported sales were
€197.3 million, up 7.7%, including a favorable forex impact of €1.9
million. At constant exchange rates, sales were
€195.4 million, up 6.7%.
Consolidated Group revenue
(IFRS)
In
millions of euros, |
Change
(%) |
Q1 2019at current exchange
rates |
Change
(%) |
Q1 2019at constant exchange
rates* |
Q1 2018Published |
Sales in Europe |
+10.0% |
93.0 |
+11.6% |
94.4 |
84.5 |
Sales in Other Markets |
+5.7% |
104.3 |
+2.4% |
101.1 |
98.7 |
Total |
+7.7% |
197.3 |
+6.7% |
195.4 |
183.2 |
In Europe, Guerbet delivered double-digit
revenue growth of 11.6% at constant exchange rates, driven largely
by strong sales in Germany and Turkey and favorable base
effect.
In the United States, sales continued their
upward trajectory, as no Dotarem generic has been launched yet.
Sales were stable in Asia, with satisfactory early revenue streams
in Japan, but an unfavorable base effect compared with the 1st
quarter 2018 for China and distributors.
Revenue generated by the Diagnostic
Imaging business increased by 6.2%, reaching €170.9
million at constant exchange rates (€171.9 million at current
exchange rates).
- A satisfactory 6.1% increase in MRI** sales,
reaching €66.4 million at constant exchange rates, and
like-for-like period and scope (€66.4 million at current exchange
rates), fueled by Dotarem® which continues to deliver good
performance, despite the generic.
- Revenue in the CT/Cath Lab** segment was
€101.7 million at constant exchange rates, up 6.7%. At current
exchange rates, revenue was €102.6 million. Optiray® sales were
improving, mainly due to a favorable base effect, while Xenetix®
was slightly down.
- The digital segment is in launch mode and made only a marginal
contribution to revenue.
In Interventional Imaging,
revenue totaled €16.2 million at constant exchange rates, an 18.4%
increase (€16.7 million at current exchange rate). There is good
momentum in this segment, although new microcatheters (DraKon® and
SeQure®) contribution to sales is still low. They have just
obtained the CE Mark which will allow their distribution on the
European market.
Targets unchanged
We expect sales to grow at a moderate pace in
2019. While the switch to direct distribution in Japan will benefit
Dotarem, it will be negatively impacted by the introduction of the
generic in new countries. Optiray sales should continue to grow,
especially in Japan. As DraKon® and SeQure® microcatheter sales
come on stream in the US and then in Europe, they will act as a
growth driver for the Group’s Interventional Imaging business.
*At constant exchange rates: amounts and rates
of growth are calculated by canceling out the exchange rate effect,
which is defined as the difference between the indicator’s value
for period N, converted at the exchange rate for period N-1,
and the indicator’s value for period N-1.
** Reminder: the MRI and CT /
Cath Lab segments now include sales of injection systems and
related services.
Upcoming events:
Publication of revenue for 1st half of
2019July 25, 2019, after trading
About Guerbet
Guerbet is a pioneer in the contrast-agent
field, with more than 90 years’ experience, and is a leader in
medical imaging worldwide. It offers a comprehensive range of
pharmaceutical products, medical devices, and services for
diagnostic and interventional imaging to improve the diagnosis and
treatment of patients. With 8% of revenue dedicated to R&D and
more than 200 employees distributed across its four centers in
France, Israel, and the United States, Guerbet is a substantial
investor in research and innovation. Guerbet (GBT) is listed on
Euronext Paris (segment B – mid caps) and generated
€790 million in revenue in 2018. For more information about
Guerbet, please visit www.guerbet.com
Forward-looking statements
Certain information contained in this press
release does not reflect historical data but constitutes
forward-looking statements. These forward-looking statements are
based on estimates, forecasts, and assumptions, including but not
limited to assumptions about the current and future strategy of the
Group and the economic environment in which the Group operates.
They involve known and unknown risks, uncertainties, and other
factors that may result in a significant difference between the
Group’s actual performance and results and those presented
explicitly or implicitly by these forward-looking statements.
These forward-looking statements are valid only
as of the date of this press release, and the Group expressly
disclaims any obligation or commitment to publish an update or
revision of the forward-looking statements contained in this press
release to reflect changes in their underlying assumptions, events,
conditions, or circumstances. The forward-looking statements
contained in this press release are for illustrative purposes only.
Forward-looking statements and information are not guarantees of
future performance and are subject to risks and uncertainties that
are difficult to predict and are generally beyond the Group’s
control. These risks and uncertainties include but are not limited
to the uncertainties inherent in research and development, future
clinical data and analyses (including after a marketing
authorization is granted), decisions by regulatory authorities
(such as the US Food and Drug Administration or the European
Medicines Agency) regarding whether and when to approve any
application for a drug, process, or biological product filed for
any such product candidates, as well as their decisions regarding
labelling and other factors that may affect the availability or
commercial potential of such product candidates. A detailed
description of the risks and uncertainties related to the Group’s
businesses can be found in Chapter 4.4 “Risk Factors” of the
Group’s Registration Document filed with the French Financial
Markets Authority (AMF) under number D-18-0387 on 25 April
2018, available on the Group’s website (www.guerbet.com).
For more information about Guerbet, please visit
www.guerbet.com
Contacts
Jerome
EstampesChief Financial
Officer+33 (0)1 45 91 50 00 |
Financial
CommunicationsBenjamin
Lehari+33 (0)1 56 88 11 25blehari@actifin.fr PressJennifer
Jullia+33 (0)1 56 88 11 19jjullia@actifin.fr |
Guerbet (EU:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024